IP Library Granted Patent US 8,440,179
Granted Patent B2
US 8,440,179 · App. 12/525,172 · Granted May 14, 2013

Agent for reducing visceral fat

Inventors: Hiroshi Kawakami (Kawagoe, JP); Yasuhiko Shiinoki (Kawagoe, JP); Yukio Kadooka (Kawagoe, JP)
Assignee: Megmilk Snow Brand Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,179
App. No.
12/525,172
Granted
May 14, 2013
Kind
B2
Abstract

Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and/or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.

Claims (9)

1. A method of reducing visceral fat of a subject, comprising:

orally administrating to the subject a composition comprising bacterial cells of lactic acid bacteria belonging to the Lactobacillus sp. and/or Lactococcus sp. and/or cultures thereof in an amount effective to reduce visceral fat of the subject,

wherein the lactic acid bacteria are one or more selected from the group consisting of Lactobacillus gasseri, Lactobacillus helveticus, Lactococcus lactis , and Lactococcus cremoris .

2. The method according to claim 1 , wherein the composition is administrated in an amount of 10 8 to 10 12 cfu per day of the bacterial cells and/or cultures thereof.

3. The method according to claim 1 , wherein the administration of the composition is continued until the ingested bacteria remain stable in the intestinal tracts.

4. The method according to claim 1 , wherein the subject shows a metabolic syndrome prior to the administration of the composition.

5. The method according to claim 1 , wherein the subject is in need of reducing visceral fat.

6. The method according to claim 5 , wherein the composition comprises the bacterial cells of lactic acid bacteria and/or cultures thereof as a main active ingredient.

7. The method according to claim 1 , wherein the lactic acid bacteria are Lactobacillus gasseri .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 027495 FRAME 0616. ASSIGNOR(S) HEREBY CONFIRMS THE NATURE OF CONVEYANCE IS AN ABSORPTION AND MERGER OF ASSIGNOR INTO ASSIGNEE, AND NOT SIMPLY A CHANGE OF NAME. Recorded Feb 2, 2012
From: SNOW BRAND MILK PRODUCTS CO., LTD.
To: MEGMILK SNOW BRAND CO., LTD.
Reel/Frame 027646/0183 →
CHANGE OF NAME Recorded Jan 6, 2012
From: SNOW BRAND MILK PRODUCTS CO., LTD.
To: MEGMILK SNOW BRAND CO., LTD.
Reel/Frame 027495/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2009
From: KAWAKAMI, HIROSHI; SHIINOKI, YASUHIKO; KADOOKA, YUKIO
To: SNOW BRAND MILK PRODUCTS CO., LTD.
Reel/Frame 023293/0476 →
Priority Claims (1)
JP 2007-053179 · Mar 2, 2007 · national
Continuity (1)
Related Publication 20100021445A1 · Jan 28, 2010